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Mevalonic acid (MVA; (R)-3,5-dihydroxy-
3-methylpentanoic acid) is a metabolic interme-
diate that is present in human and rat plasma, 
and excreted into urine [1,2]. It is produced 
from 3-hydroxy-3-methylglutaryl coenzyme 
A (HMG-CoA) by HMG-CoA reductase [3], 
which is the rate-limiting enzyme of the multi-
compartment mevalonate pathway (Figure 1A). 
As an early intermediate of the mevalonate 
pathway, MVA is essential for the synthesis of 
cholesterol and isoprenyl intermediates, which 
are key to the post-translational modification 
(isoprenylation) and regulation of an array of 
proteins [4], and the formation of isoprenoids 
such as heme A and ubiquinone. Consequently, 
the pathway is tightly regulated by a complex 
feedback mechanism that governs the activity of 
HMG-CoA reductase according to cellular needs 
[5]. The mevalonate pathway has been studied in 
numerous areas of biomedical research including 
HMG-CoA reductase inhibitors administered 
for the treatment of hyperlipidemia [6], the diag-
nosis of mevalonate kinase deficiency (charac-
terized by mevalonic aciduria) [7] and recently 
in the treatment of cancer [8,9]. Furthermore, 
HMG-CoA reductase activity has been observed 
to increase upon acute renal injury, causing cho-
lesterol accumulation [10]. As such, the mevalon-
ate pathway is an important target in human 
pathology, toxicology and pharmacotherapy [11]. 
As the only precursor of isoprenyl intermediates 
that is committed to the pathway and present in 
accessible biofluids, MVA is effectively the only 
metabolite that might be a biomarker of total 
pathway flux in vivo.
MVA is synthesized predominantly in the 
liver [12] and most of the metabolite in plasma is 
taken up by the kidneys, where it is incorporated 
into squalene and sterols, catabolized or excreted 
in urine [12–14]. Urinary output accounts for 29% 
of the total renal flux of MVA [1]. The plasma 
concentration and urinary excretion of MVA 
display parallel diurnal variations that track 
oscillations of cholesterol synthesis [14–16], in 
man [14] and in preclinical models [17,18]. Diurnal 
variations in HMG-CoA reductase activity have 
been attributed to food intake, with the peak of 
activity occurring 3–6 h post feeding [2,19,20]. 
Likewise, Kopito et al. observed a fourfold, feed-
ing-induced rise in serum MVA concentration 
[2]. However, no attempt has been made to define 
diurnal variation of urinary MVA excretion in 
rats, as it occurs in man [2].
The multifarious significance of the meval-
onate pathway, for the study of human physiol-
ogy, disease and pharmacology, highlights the 
need for a validated (accurate, precise and site 
transferable) translational assay of MVA in non-
clinical species and humans. Existing literature 
suggests a normal range of 116–1227 ng/ml 
MVA in human urine [21,22], but the rat has a 
higher steady state concentration of MVA in 
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plasma compared with man [23], with a range of 
10.5–65.3 ng/ml in Sprague-Dawley rat plasma 
[16,23], compared with 0.4–9.9 ng/ml in human 
plasma [21,24–26]. The administration of HMG-
CoA reductase inhibitors to humans causes a 
30–40% reduction of plasma MVA [27]. Pub-
lished data on urinary MVA excretion in non-
clinical species are lacking, although one report 
observed a MVA clearance of 350 pmol/min in 
rats [1]. Consequently, a robust analytical method 
that can quantify MVA in urine for clinical and 
nonclinical research is likely to require a wide 
dynamic range.
MVA is a polar molecule and at low pH under-
goes spontaneous cyclisation to its lactone form 
(mevalonolactone [MVL]; Figure 1B). More 
recent quantification methods have favored the 
use of LC–MS/MS for quantifying MVA in 
human plasma [24,25,27], or human plasma and 
urine [21]. To date there is no validated method 
for MVA in the literature that can be used to 
quantify the biomarker in rat and human urine. 
Owing to its potential for high specificity and 
sensitivity, LC–MS/MS is an attractive analyti-
cal platform for biomarker quantification, but a 
frequent criticism is its perceived lack of inter-
laboratory reproducibility [28], hence it would be 
advantageous to establish a LC–MS/MS based 
MVA quantification method, which has been 
validated for use in different laboratories.
The long-established concepts of drug bioana-
lysis and bioanalytical method validation do not 
wholly apply to the quantification of endogenous 
molecules such as MVA; as such, ‘fit-for-purpose’ 
biomarker method development and validation 
guidelines have been established recently [29,30], 
which include routine assessment of dynamic 
range, analytical precision and accuracy, relative 
accuracy plus validation of calibration standards 
made in surrogate matrices. Herein we detail the 
first validation of a fit-for-purpose translational 
MVA assay and its transfer between two separate 
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Figure 1. Mevalonic acid: metabolic pathway and analytical chemistry. (A) The mevalonate 
pathway synthesises MVA from HMG-CoA through the rate-limiting enzyme 3-hydroxy-3-
methylglutaryl coenzyme A reductase. This enzyme reaction is inhibited by the statin class of drugs 
in the treatment of hyperlipidemia; thereby serum and urinary MVA can be quantified to measure 
drug efficacy. (B) MVA is converted to its less polar lactone at low pH for quantification by 
LC–MS/MS. (C) Optimization of the pH-dependent conversion of MVA to mevalonolactone. 
(D) Optimization of the rate of conversion of MVA to mevalonolactone at pH 2 and ambient 
temperature or 60°C. 
HMG-CoA: 3-hydroxy-3-methylglutaryl coenzyme A; MVA: Mevalonic acid; MVL: Mevalonolactone.
Key Term
Translational medicine: 
Scientific approach that aims to 
bridge the gap between 
nonclinical and clinical research 
with the goal of benefiting 
human health. The initiative has 
garnered enormous investment 
throughout the research and 
health community and in the 
United Kingdom, the Medical 
Research Council allocated 
GB£354 million to this area over 
a 4 year period from 2011.
ReseaRch aRticle |  Rodrigues, Maggs, McWilliam et al.
Bioanalysis (2014) 6(7)920 future science group
laboratories. We confirm the utility of this 
robust and validated assay for translational 
medicine by testing its biomarker potential in 
rats and humans, and demonstrating the diur-
nal variation of MVA excretion that is predicted 
by hepatic microsomal HMG-CoA reductase 
activity.
Materials & methods
 Materials
(R)-MVA (purity ~96%) and MVL (purity 
~97%) were obtained from Sigma-Aldrich 
(St Louis, MO, USA). 4,4,5,5-Tetradeutero-
MVL (d
4
-MVL, purity 97%) was obtained 
from CDN Isotopes (Pointe-Clare, Quebec, 
Canada). Methanol, ethyl acetate and for-
mic acid were of analytical grade and were 
obtained from Fisher Scientific (Loughbor-
ough, UK). Urine for method development was 
obtained by spot collection from five healthy 
volunteers (two male, three female, mean age 
23.2 ± 1.3 years) not subject to dietary or bever-
age constraints and from male Sprague-Dawley 
rats (150–250 g, pool of 12 donors) (Alderley 
Park, AstraZeneca). The urine was stored at 
-20°C. Urine for the rat biomarker investiga-
tion was collected from different animals via 
single housing in metabolic cages for 12 h 
between time points 10:00 and 22:00 (n = 8) 
or 22:00 and 10:00 h (n = 8), and stored at 
-80°C until ana lysis. The animals had free 
access to food and water throughout the 12 h 
periods. The phases of the illumination cycle in 
the animal accommodation were 08:00–20:00 
(light) and 20:00–08:00 (dark). Protocols 
were undertaken in accordance with a license 
granted under the Animals (Scientific Proce-
dures) Act 1986 and approved by the University 
of Liverpool Ethics Committee. Urine for the 
human biomarker investigation was obtained 
by spot collection in the morning (time points 
range 05:15–08:50) and evening (range 
17:30–22:30) from 25 healthy children (mean 
age 9.10 years, range 0.9–16.7 years). Children 
were recruited from schools and a nursery with 
informed written consent obtained from carers 
or guardians on the behalf of the participating 
children. The study was conducted with the 
approval of the Liverpool East Research Eth-
ics Committee. Urine samples were collected 
from each child by an age-appropriate method, 
normally a clean catch urine sample into a ster-
ile container. Samples were centrifuged, ali-
quoted into smaller volumes, then frozen and 
stored at -80°C.
 Optimization of the pH-dependent 
conversion of MVA to MVL
MVA (0.01, 0.1 and 0.5 µg/ml) was dissolved in 
water-methanol (9:1, v/v) that had been adjusted 
to various pH values between 2 and 6 by addition 
of formic acid. After 90 min at ambient tempera-
ture, aliquots (10 µl) were taken and analyzed 
by a LC–MS/MS method to identify the maxi-
mal peak area of MVL. The optimal pH (pH 2) 
was selected for further development. 0.1 µg/ml 
MVA was incubated at pH 2 and ambient tem-
perature, 37 or 60°C with aliquots taken at 0, 15, 
30, 60, 90, 120, and 180 min and analyzed by 
LC–MS/MS. MVL yield was also determined 
by overnight incubation at ambient temperature 
and pH 2. The optimal temperature (60°C) and 
incubation period (minimum of 15 min) for the 
extent of the reaction were chosen. Aliquots of 
MVL (0.1 µg/ml in water-methanol 9:1 v/v at 
pH 2) were incubated at 60°C for 120 min to 
establish analyte stability. The percentage of 
MVA converted to MVL was calculated from 
the concentration of MVL in MVA standards 
(4 and 6 µg/ml in distilled water) and in rat 
(n = 3) and human (n = 3) donors, that had 
been acidified (pH 2) and incubated at 60°C for 
a minimum of 15 min. Intra-day (n = 3 analyses 
per standard) and inter-day (n = 18, representing 
three analyses per standard, two standards and 
analyses on 3 days) variation of the conversion 
was also determined. The endogenous presence 
of MVL in human and rat urine was determined 
by ana lysis of 10 µl aliquots of unprocessed urine 
(from three rat and three human donors) using 
LC–MS/MS. 
 Extraction of MVL
Recovery of MVL from urine (50 µl) was 
achieved by LLE with ethyl acetate (1:4, v/v). The 
recoveries of MVL (0.4–6.0 µg/ml) and the IS, 
d
4
-MVL (0.15 µg/ml), were determined by spik-
ing MVL and IS (dissolved in acidified methanol 
3% formic acid) into buffer (0.1 M potassium 
phosphate, adjusted to pH 2 with orthophospho-
ric acid) or into acidified rat (n = 3) or human 
(n = 3) urine . Samples were shaken vigorously for 
10 min at ambient temperature and centrifuged 
at 8700 g for 10 min. Approximately 600 µl of the 
organic layer was taken and evaporated to dryness 
under oxygen-free nitrogen. The samples were 
reconstituted in 200 µl of water-methanol (9:1, 
v/v) containing 0.1% formic acid (pH 2.4) before 
injection of 10 µl of solution on to the HPLC 
column. The extracted compounds were assayed 
by comparison with standards (water-methanol 
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9:1, v/v, 0.1% formic acid) of the same concen-
tration. For the urine extraction recovery, the 
endogenous concentration of MVL was factored 
into the calculation.
 Calibration standards
To determine the sensitivity, range, precision and 
accuracy of the LC–MS/MS method, MVL stan-
dards (0.078–10 µg/ml in pH 2 buffer; n = 3) 
were spiked with IS (final concentration, 0.15 µg/
ml), extracted with ethyl acetate, reconstituted 
in water-methanol-formic acid (9:1:0.1, v/v) 
and quantified by LC–MS/MS. Independently 
prepared QC MVL standards and a validation 
sample (VS, a small population sample, in this 
case of pooled human or rat urine, that is rep-
resentative of the individual analytical samples) 
were prepared at the beginning of the validation, 
and analyzed alongside analytical samples and 
calibration standards to confirm batch acceptabil-
ity and between-batch reproducibility of preci-
sion, accuracy and stability. Pooled human urine 
was prepared by mixing equal volumes of urine 
from five donors. The LOD was designated to be 
the concentration of extracted MVL with a peak 
height greater than three-times the background 
signal. The LLOQ and ULOQ were, respec-
tively, the lowest and highest concentrations of 
extracted MVL with acceptable accuracy and 
precision. The acceptance criterion of precision 
was 15% coefficient of variation, or 20% for the 
low QC and LLOQ, while the acceptance crite-
rion of accuracy was 85–115% or 80–120% for 
the low QC and LLOQ [29], which was deter-
mined by extraction of each of the nine calibra-
tion standards (three replicates) or three QC (six 
replicates) in three independent batches. A batch 
was deemed acceptable if more than four of the 
six QC replicates were within 85–115% of the 
set value, in accordance with biomarker assay 
validation guidelines [29]. LC–MS/MS carryover 
was determined by repeat injection of 10 µl of a 
10 µg/ml MVL standard followed by injection 
and ana lysis of 10 µl of a blank reconstitution 
solution. 
 Assessment of matrix effects
Rat and human urine (50 µl aliquots from five 
donors) was acidified, extracted and recon-
stituted, and spiked with MVL and IS (final 
concentration 5 µg/ml) and serially diluted 
(water-methanol 9:1 v/v, 0.1% formic acid). 
The effect of dilution on the analyte/IS ratio 
was measured by the LC–MS/MS method. An 
ionization suppression/enhancement experiment 
was conducted using the postcolumn infusion 
method. Due to the endogenous presence of the 
analyte in acidified urine, a solution of d
4
-MVL 
(0.1 µg/ml) in water-methanol containing for-
mic acid (9:1 v/v, 0.1%) was infused directly into 
the MS source at a constant rate of 10 µl/min 
(HPLC eluate entered the source at 280 µl/min) 
and 10 µl of a reconstituted ethyl acetate extract 
of an acidified human or rat urine sample (10 µl) 
was injected on to the HPLC column. The 
continuous MS/MS response to the d
4
-MVL 
(m/z 135→75) was monitored.
 Addition recovery
Human or rat urine (study samples) was spiked 
with a high concentration of MVA (in order to 
minimize the contributory effect of endogenous 
MVA) and the percentage recovery was used to 
evaluate relative accuracy. MVA in spiked (0.1, 
0.5 or 4 µg/ml) and nonspiked human and rat 
urine (multiple donors) was converted to MVL, 
extracted, reconstituted and quantified by the 
LC–MS/MS method. The concentration of 
MVA in nonspiked urine was subtracted from 
the concentration determined in the aliquot of 
spiked urine and the percentage recovery was 
calculated.
 Stability
Stability of MVL in the QC standards was deter-
mined by storage at room temperature, 4°C and 
at -20°C for 14 days. Freeze–thaw cycles of QC 
standards at -20°C and room temperature were 
also carried out. The stability of MVL in recon-
stituted extracts of urine samples at 4°C in the 
autosampler was also determined.
 Validated method 
Calibration standards were prepared on the day 
of ana lysis from 0.0156 to 10 µg/ml at pH 2 
with IS (0.15 µg/ml). Aqueous QC standards 
(0.045, 2 and 6 µg/ml in laboratory 1 and 0.1, 
4 and 9 µg/ml in laboratory 2, at pH 2) and 
a pooled rat urine or human urine VS were 
prepared at the start of the validation process 
and stored at -20°C. Urine or MVL calibration 
standards (50 µl) were incubated with 148 µl 
of buffer (0.1 M potassium phosphate, pH 2) 
at 60°C for 25 min. After cooling to ambi-
ent temperature, samples and standards were 
spiked with 2 µl of d
4
-MVL solution (15 µg/ml 
acidified aqueous stock, final concentration 
0.15 µg/ml). The analytes were extracted with 
800 µl of ethyl acetate: the samples were shaken 
vigorously for a minimum of 10 min at ambient 
Key Term
Biomarker assay 
validation: Biomarker assays 
are distinct from PK bioana lysis. 
Assays for novel biomarkers 
frequently pose unique analytical 
challenges (e.g., no true blank 
matrix) and adherence to 
validation parameters is often 
impractical. Traditional 
regulatory bioana lysis guidelines 
are considered as a framework 
for biomarker assay validation 
and the process accommodates 
the characteristics of the 
analyte, the limitations of the 
analytical platform and the 
intended use of the assay with a 
‘fit-for-purpose’ approach.
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temperature before centrifuging at 8700 g for 
10 min. Approximately 600 µl of the organic 
layer were removed, evaporated to dry residue 
under oxygen-free nitrogen and reconstituted in 
200 µl of water-methanol (9:1, v/v) containing 
0.1% formic acid before injection of 10 µl of 
solution on to the HPLC column. 
Chromatographic separation was achieved 
on an Acquity UPLC® (Waters, Millford, MA, 
USA) (laboratory 1) or Dionex UltiMate® 3000 
LC system (Fisher Scientific, Loughborough, 
UK) (laboratory 2) with a Synergi™ 2.5-µm 
Hydro RP column (100 × 2.0 mm; Phenomenex, 
Macclesfield, UK). The LC method employed 
solvent A (water-0.1% formic acid) and solvent 
B (methanol-0.1% formic acid) (TABle 1). The 
LC–MS/MS ana lysis time was 5 min per sample. 
A MRM method was optimized on an AB Sciex 
4000 QTRAP® instrument (Foster City, CA, 
USA) in positive-ion mode using automatic and 
manual tuning with aqueous standards of MVL. 
The precursor ion for MVL was m/z 131, and 
the transition m/z 131→69.4 was used for the 
quantification of MVL with reporter transitions 
at m/z 131→113 and m/z 131→71. The reporter 
transitions and retention time of MVL conferred 
specificity. The IS d
4
-MVL was monitored at 
m/z 135→75 in laboratory 1 and m/z 135→73 
in laboratory 2. The following conditions were 
used for LC–MS/MS acquisition: curtain gas 
setting, 10.0; collision gas, 4.0; IonSpray volt-
age, 5500 V; temperature, 450°C; ion source 
gas 1, 90 in laboratory 1 (20 in laboratory 2); 
ion source gas 2, 20; interface heater, on; dwell 
time, 150 ms; declustering potential, 50 V; Q1 
and Q3 resolution, high. Individual transition 
parameters are given in TABle 2.
 Application to study samples
MVA was quantified in urine acquired from 
male Sprague-Dawley rats in 12 h collections 
(time range 10:00–22:00 or 22:00–10:00) 
and urine from 25 healthy children obtained 
by spot collection in the morning (time 
range 05:15–08:50) and evening (time range 
17:30–22:30).
 Calculation & normalization
Quantification of MVA in urine was achieved 
by linear regression, plotting the nominal 
MVL concentration against the analyte-IS 
peak area ratio. The calculated concentrations 
were adjusted according to the within-batch 
estimate of the conversion of MVA to MVL. 
The simplest calibration model was selected for 
quantifying the concentration of analyte in stan-
dards and urine in accordance with the guide-
lines for ‘fit-for-purpose’ biomarker method 
validation [29]. 
The MVA concentration was normalized 
to the urinary creatinine concentration (UCr) 
as determined by the Jaffe-based assay: urine 
(25 µl of urine diluted one in 25) was incubated 
with 125 µl of alkaline picrate solution (0.14 M 
NaOH, 10 mM Na
2
HPO
4
, 90 mM sodium 
borate, 10 mM sodium dodecyl sulphate, 25% 
v/v picric acid, 2.7% v/v DMSO) for 2 min at 
room temperature before addition of 5 µl of acid 
solution (10:2:88 v/v acetic acid:concentrated 
H
2
SO
4
:distilled water) and further incubation 
at room temperature for 10 min with shaking. 
Plates were read at 490 nm and creatinine was 
estimated using creatinine calibration standards. 
Data are reported as nanograms (or micro-
grams) of MVA per milligram of creatinine 
(ng/mg UCr).
Results
 pH-dependent conversion of MVA to MVL
The acid-catalyzed formation of MVL from MVA 
was optimized by incubating aqueous standards 
at a range of pH values (Figure 1C). Below pH 3 
the amounts of MVA and MVL were observed 
to decrease and increase, respectively. Based on 
Table 1. HPLC conditions for the ana lysis of extracted urine samples, standards 
and QCs.
Time (min) %A %B Flow rate (ml/min)
Initial 95 5 0.30
2.00 95 5 0.30
2.01 90 10 0.30
2.70 90 10 0.30
2.80 95 5 0.30
5.00 95 5 0.30
Phenomenex Synergi™ Hydro RP column (2.5 µm, 100 A, 100 × 2.00 mm) linked to an Acquity UPLC® or Dionex Ultimate® 
3000 and the 4000 QTRAP®. The mobile phase is at pH 2.4.
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these results, the production of MVL at pH 2 
was examined over 180 min at ambient tempera-
ture, 37 and 60°C. No significant difference was 
observed between the rate of MVL production at 
ambient and physiological temperature; incuba-
tions at 60°C for 25 min had a greater rate of 
MVL production (Figure 1D). The percentage 
converted to MVL overnight at ambient tempera-
ture was not significantly different from the yield 
of MVL after 25 min at 60°C: 70.8 ± 3.9% (n = 6) 
versus 67.5 ± 1.3% (n = 6), respectively; therefore 
an overnight incubation offered no advantage. 
The percentage conversion of MVA to MVL in 
aqueous standards under the optimal conditions 
was 69.5 ± 4.4% (day 1; n = 6), 66.0 ± 3.9% 
(day 2; n = 6) and 67.5 ± 1.3% (day 3; n = 6). 
In three rat urine donors the percent conversion 
of MVA to MVL was 73.8 ± 6.5% and in three 
human donors 70.6 ± 2.7%; aqueous standards 
in this experiment gave an equivalent conversion 
of 71.1 ± 2.5%. Data are given as mean ± SD. 
Inter-day variation of 3.6% was observed and, 
as a result, aqueous MVA standards were con-
verted at the same time as study samples to deter-
mine percentage conversion for each batch. In 
the ana lysis of 10 µl of unprocessed rat (n = 3) 
and human (n = 3) urine by the LC–MS/MS 
method, MVL was not detected. 
 Extraction recovery
The analyte and IS were not extracted by ethyl 
acetate to the same extent, with 72.7 ± 2.1% 
(n = 6) of the analyte recovered compared 
with 34.4 ± 3.5% IS in laboratory 1. In labora-
tory 2 it was observed that extraction recovery 
of the analyte and IS was lower at 33.7 ± 1.0% 
(n = 6) and 17.5 ± 1.7% (n = 5), respectively, 
but the analyte-IS peak area relationship was 
still reproducible, linear and accurately quan-
tifiable by LC–MS/MS. Increasing the extrac-
tion time to 30 min in laboratory 2 gave equiva-
lent recoveries of analyte (73.6 ± 6.3%) and 
IS (38.5 ± 4.3%) as observed in laboratory 1. 
The extraction recovery of the analyte and IS 
was assessed in human (n = 3) and rat (n = 3) 
donors. The mean extraction recovery of 0.4, 1.0 
and 6.0 µg/ml MVL from three rat urine donors 
was 64.0 ± 8.1%, 62.5 ± 4.8% and 54.3 ± 5.0%, 
respectively, and the mean recovery of 0.15 µg/ml 
IS was 27.9 ± 3.3%. The mean extraction recov-
ery of 0.4, 1.0 and 6.0 µg/ml MVL from three 
human donors was 72.8 ± 16.1%, 62.1 ± 4.4% 
and 64.7 ± 8.7%, and the mean recovery of 
0.15 µg/ml IS was 31.5 ± 3.3%. The peak area 
ratio of analyte to IS corrects for the variabil-
ity in the extraction recovery between samples, 
enabling the accurate quantification of MVL. 
The peak areas of MVL and the IS in calibration 
standards and samples of equivalent concentra-
tion were similar. As an example the mean peak 
area of MVL in one rat study sample was deter-
mined to be 2.5 × 106 ± 5.2 × 104 and, using 
the analyte/IS peak area ratio, was calculated 
to be 5.9 µg/ml MVL. The closest standard, a 
QC at 6 µg/ml, had a similar MVL peak area of 
2.8 × 106 ± 2.7 × 105. The IS peak area for the 
rat urine sample was 1.2 × 105 ± 3.2 × 103 and for 
the QC was 1.3 × 105 ± 7.0 × 103, giving ratios of 
20.8 and 21.5, respectively. The extracted IS peak 
areas varied by 7.9% across the rat urine study 
and by 16.0% across the human urine study.
 Calibration range, accuracy & LOQ
Several weighted regression models (1/x, 1/x2, 
1/x3) were tested to improve the residuals in 
the calibration model [31], see SupplemenTAry 
TABle 1. The best model was linear and forced 
through the origin, with acceptable precision 
and accuracy across the analytical range with 
R2 > 0.99 without the need to weight the data 
(Figure 2A). The LOD of extracted MVL was 
0.0078 µg/ml. The LLOQ was 0.0156 µg/ml in 
laboratory 1 and 0.0313 µg/ml in laboratory 2; 
the ULOQ was 10 µg/ml. Independently pre-
pared QC standards also reached acceptable 
precision and accuracy in both laboratory 1 
and laboratory 2; individual data are shown in 
TABleS 3 & 4. Carryover of the analyte to sub-
sequent blank injections on the LC–MS/MS 
was not detected.
Table 2. MS parameters for each transition in the MRM method for laboratory 1 and laboratory 2.
Laboratory 1 Laboratory 2
Analyte Q1 mass 
(m/z)
Q3 mass 
(m/z)
Collision 
energy (eV)
Collision exit 
potential (V)
Q3 mass 
(m/z)
Collision 
energy (eV)
Collision exit 
potential (V)
Mevalonolactone 130.956 113.1 13 8 113.1 13 8
Mevalonolactone 130.956 71.0 20 12 71 20 12
Mevalonolactone 130.956 69.4 15 10 69.4 20 20
IS 134.945 75.0 20 12 73.4 15 5
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 Parallelism of rat urine to surrogate matrix 
To validate the utility of a surrogate matrix 
for the calibration standards, rat (n = 5) and 
human (n = 5) urine that had been acidified, 
extracted and reconstituted was serially diluted, 
and the analyte and IS response was determined 
by LC–MS/MS (Figure 2B & C). The observed 
analyte response remained within 20% of what 
was expected in both rat and human urine up 
to a dilution of one in 128. The observed IS 
response only remained within 20% of the 
expected response in both rat and human urine 
up to a dilution of one in 16, as further dilution 
reduced the IS response below the LOD. These 
data suggest that the rat and human urine matrix 
has no significant effect on the MS detection of 
MVL and the IS. 
 Matrix effects
Matrix effects were further investigated by 
postcolumn infusion of d
4
-MVL and injection 
of 10 µl of a reconstituted ethyl acetate extract 
of acidified human or rat urine. The MS/MS 
response of the IS was monitored throughout 
the elution and there was no significant suppres-
sion or enhancement of the signal for d
4
-MVL 
at or around the retention time of the analyte 
(Figure 3A & B).
 Relative accuracy
Rat and human urine spiked (0.1, 0.5 or 4 µg/ml 
MVA) and nonspiked was extracted and assayed 
to determine relative accuracy. The mean con-
centration of MVL in the nonspiked urine was 
subtracted from that of the spiked urine. In 
laboratory 1, the recovery of a 4 µg/ml spike 
in rat urine was 105.7 ± 9.9%. In laboratory 2, 
the recovery of the 0.1, 0.5 or 0.4 µg/ml spike 
in rat urine was 96.0 ± 7.6%, 111.0 ± 6.9% and 
105.9 ± 2.3%, respectively. Recovery of the 
0.1, 0.5 or 0.4 µg/ml spike in human urine was 
assessed in laboratory 2 and was calculated to 
be 96.0 ± 4.8%, 118.2 ± 3.5 and 107.3 ± 0.4%, 
respectively. Data are mean ± SD. Full recovery 
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Figure 2. Validation of the surrogate matrix for the mevalonolactone calibration and QC 
standards. (A) The linear relationship between nominal concentration and the analyte to IS ratio. 
Independently prepared QC standards were within ±15% of the nominal concentration; data 
shown are mean values of three batches (n = 3 for each batch) from laboratory 1. (B) Dilution 
linearity of mevalonolactone extracted from rat urine (n = 5). (C) Dilution linearity of 
mevalonolactone extracted from human urine (n = 5). Dilution linearity of the analyte/IS peak area 
ratio confirms the parallelism of the surrogate matrix. 
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of the spiked analyte from multiple donors sug-
gests that this method can be used for the accu-
rate quantification of MVA in both human and 
rat urine. 
 Reproducibility
Reproducibility of the full extraction and ana lysis 
method was determined by quantifying MVA in 
rat and human urine (VS) divided into three 
batches stored at -20°C. MVA was quantified on 
three separate occasions from each of these batches 
(n = 3 per ana lysis) over 20 days (Figure 4A & B). 
Within-batch variation was similar between labo-
ratories, with 2.01–4.58% coefficient of variation 
in laboratory 1 and 1.45–5.25% in laboratory 2; 
while between-batch variation was 6.15% in 
laboratory 1 and 6.35% in laboratory 2.
 Stability
MVL QC standards were stable at room tempera-
ture, 4°C and at -20°C across 14 days, and at 60°C 
for 120 min (TABle 5). Freeze–thawing did not 
affect the integrity of aqueous standards. 
 Biomarker application
MVA was quantified in the urine collected 
from male Sprague-Dawley rats during two 
12 h collections, time ranges 10:00–22:00 
and 22:00–10:00 (Figure 4C). The excretion 
of MVA was significantly greater (unpaired 
t-test; p < 0.0001) in urine collected during 
the time range 22:00–10:00 (6.2–13.0 µg/mg 
UCr; mean 9.7 ± 2.3 µg/mg UCr) compared 
with the time range 10:00–22:00 (1.6–5.2 µg/
mg UCr; mean 3.4 ± 1.3 µg/mg UCr). When 
expressed as total MVA excretion by factoring in 
urine volume, the diurnal differences remained 
and urine collected in time range 22:00–10:00 
represented a mean excretion of 110.0 ± 27.8 µg 
MVA/12 h (81.7–153.2 µg) compared with 
urine collected in time range 10:00–22:00 with 
a mean excretion of 21.5 ± 6.6 µg MVA/12 h 
(12.8–33.1 µg).
MVA was also quantified in paired morning 
and evening urines obtained by spot collection 
from healthy children (n = 25). The excretion of 
MVA in evening spot collections had a median 
of 292.4 ng/mg UCr (n = 25, inter quartile range 
245.4 ng/mg UCr), whereas the median concen-
tration of MVA in morning spot collections was 
427.0 ng/mg UCr (n = 25, inter quartile range 
230.1 ng/mg UCr). The paired and mean data 
are represented in Figure 4D & e; in 15 out of 
25 pairs, morning collections had significantly 
greater concentrations of MVA than evening T
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collections (p < 0.05; t-test, paired, two-sided) 
where the morning excretion was, on average, 
105% greater; however, in four individuals the 
concentration of MVA was significantly greater 
in the evening collection (p < 0.005; t-test, 
paired, two-sided). The remaining six morning 
and evening pairs had numerical differences but 
were not statistically significant.
Discussion
Translational studies of the mevalonate pathway 
are hindered by the lack of a simple and vali-
dated, cross-species quantification method for 
the urinary biomarker of HMG-CoA reductase 
activity, MVA. The only published LC–MS/MS 
assay of urinary MVA has a short dynamic range 
of 20–1000 ng/ml validated in human urine; in 
addition the protocol requires an initial sample 
volume of 125 µl [21]. We have developed, vali-
dated and applied an assay for MVA by LC–MS/
MS that can be used for the ana lysis of rat and 
human urine, and can be transferred between 
laboratories. With a substantial dynamic range 
(0.0156–10 µg/ml), the assay is sufficient to 
determine normal biological and perturbed con-
centrations of MVA in both rat and human urine. 
Administration of statins is known to reduce 
the production of MVA by 30–40% [6,32,33]. 
Given that the physiological urinary concentra-
tion of MVA in humans ranges between 116 
and 1227 ng/ml, the validated dynamic range 
of this assay will comfortably address perturbed 
MVA biosynthesis. The assay also benefits from 
requiring only 50 µl of urine, making the assay 
applicable where sample volumes are limited 
(e.g., rodent studies), and a short analytical 
run-time of 5 min. 
This method builds upon published methods, 
incorporating acid-catalyzed conversion of MVA 
to its lactone form MVL [21,24,25], extraction of 
the lactone and the IS with ethyl acetate [25], 
and ana lysis by positive-ion LC–MS/MS [24,25], 
but it is validated to a large dynamic range to 
encompass MVA quantification in human and 
rat urine, has an optimized MVA→MVL con-
version step, is without matrix effects and has 
been demonstrated to transfer between ana-
lytical laboratories. During the inter-laboratory 
validation we observed an increase in the LLOQ 
from 15.6 ng/ml in laboratory 1 to 31.3 ng/ml 
in laboratory 2, which could be explained by 
the extraction recovery in laboratory 2; which 
was approximately 50% lower than in labora-
tory 1. Different shaker equipment was used 
in the two laboratories, which may account for T
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the disparity, however, increasing the extraction 
period to 30 min in laboratory 2 gave equiva-
lent recoveries to laboratory 1. Therefore, when 
transferring this method to other laboratories 
and using different processing equipment, the 
extraction process must be re-optimized in order 
to retain sufficient sensitivity.
The IS was chosen to correct for between-sam-
ple inconsistencies. Ideally, the IS should behave 
in the same manner as the analyte throughout 
the analytical method. Our data have shown 
that the extraction recovery of the d
4
-MVL was 
approximately 50% lower than MVL and had 
a fractionally earlier elution time (2.05 min) 
relative to the analyte (2.10 min) in the polar 
reversed-phase HPLC method, which could 
suggest that d
4
-MVL is more polar than MVL. 
Similar observations of reversed-phase HPLC 
resolution and different extraction recoveries 
between a low molecular weight analyte and its 
d
4
-IS have been reported [34,35]. Despite this, the 
analyte-IS relationship was consistent and linear, 
as shown by the validation. Therefore, these dif-
ferences in behavior between analyte and IS are 
not limiting for the quantification of MVA, and 
d
4
-MVL, which was also used successfully in 
another published method [25], is a suitable IS.
The use of MS/MS to assay MVL derived 
from MVA in urine encountered a significant 
selectivity challenge. In extracts of rat urine, 
0
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Figure 3. Mevalonolactone assay: assessment of matrix effects and assay selectivity. LC–MS/MS chromatograms showing the 
absence of ionisation suppression/enhancement of the IS signal (m/z 135→75 for d4-mevalonolactone; retention time, 2.05 min) by 
co-eluting materials extracted from (A) the acidified rat and (B) human urine matrix with ethyl acetate. (C) The extracted ion 
chromatogram of a reconstituted ethyl acetate extract (10 µl injection) of acidified rat urine (50 µl) showing mevalonolactone derived 
from endogenous mevalonic acid calculated to be at a concentration of 3.6 ± 0.06 µg/ml and a minor, unidentified, noninterfering 
compound eluting at 3.5 min. 
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single-reaction monitoring with m/z 131→69.4 
detected an isobaric compound that differed 
from MVL in retention time (Figure 3C). 
This compound was left uncharacterized as its 
presence did not interfere with the quantification 
of the analyte. However, we used a combination 
of chromatographic retention time and MRM 
reporter transitions to confer enhanced speci-
ficity on our assay. MVA is a very polar com-
pound and was found to be incompatible with a 
number of widely used reversed-phase columns. 
Screening of several column chemistries identi-
fied a reversed-phase polar end-capped column 
that retained MVA and MVL satisfactorily.
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Figure 4. Reproducibility of mevalonic acid determination on 3 separate days. For (A) a rat 
validation sample and (B) a human validation sample. (C) Concentration of urinary MVA 
determined in 12 h collections from male Sprague-Dawley rats displayed as mean, upper and lower 
quartiles with the range (n = 8) and mean of each individual (n = 3). (D) Concentration of MVA in 
urine obtained by spot collection from healthy human children in the evening and the following 
morning; data are plotted as the mean concentration (n = 3) determined for each morning and 
evening pair. (E) Mean concentration of urinary MVA in the statistically significant morning and 
evening spot collections from healthy human children (n = 19) with standard error. 
MVA: Mevalonic acid.
Table 5. Stability of aqueous mevalonolactone standards at the LLOQ and QC levels assessed after three cycles 
of freeze–thawing and at room temperature, 4 and -20°C for 14 days. Data are presented as the mean 
percentage recovery ± SD (n = 3). 
Storage 
conditions
LLOQ Low QC Mid QC High QC
Mean 
recovery (%)
SD (%) Mean 
recovery (%)
SD (%) Mean 
recovery (%)
SD (%) Mean 
recovery (%)
SD (%)
-20° freeze–thaw 100.5 1.0 100.1 1.4 100.9 1.7 101.7 2.5
Room temperature 
14 days
96.8 1.2 95.2 1.5 98.7 0.8 96.7 1.7
4°C 14 days 98.0 2.8 96.9 3.4 96.5 2.5 96.1 0.2
-20°C 14 days 96.0 2.3 95.0 1.7 96.1 1.4 94.4 0.2
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The high endogenous concentrations of MVA 
in rat and human urine negate the use of ‘blank’ 
matrix for calibration standards. Calibration 
standards of MVL were prepared in pH 2 buf-
fer, extracted and reconstituted in the same man-
ner as urine. The use of a surrogate matrix was 
validated by demonstrating that the human and 
rat urine matrix did not affect the percentage of 
MVA converted to MVL, the extraction recov-
ery of MVL and the IS, and the MS response 
of the analyte and IS, a phenomenon termed 
‘parallelism’. By analyzing the effect of matrix 
compared with aqueous standards at each stage of 
the assay, we found that the urine matrix had no 
appreciable bearing on the processing, detection 
and quantification of MVA. 
Matrix effects are commonly encountered in 
electrospray ionization when a matrix component 
that co-elutes with the analyte(s), but may not 
be detected in the MRM channel, attenuates or 
enhances the MS signal, and consequently com-
promises accuracy. Jemal et al. experienced exten-
sive suppressive matrix effects when they used 
negative-ion detection of MVA regenerated from 
MVL to quantify MVA in human urine [21]. We 
exploited the [M+H]+ precursor ion generated 
abundantly by an eluent containing formic acid 
instead of the [M+NH
4
]+ precursor generated by 
ammonium formate eluents [24,25]. We did not 
encounter suppression or enhancement of the 
positive-ion d
4
-MVL signal in the postcolumn 
infusion experiment and the addition recovery 
experiment gave near 100% recovery from rat 
and human urine. 
The stability of MVA in various matrices, 
including urine, has been widely cited in the 
literature. In human plasma there was <6.7% 
change from baseline over 16 months under vari-
ous storage conditions [24]. Similarly, in water, 
urine and plasma there was <8.2% change 
from baseline for at least 7 weeks [21]. We have 
included interim stability data from storage 
and freeze–thaw experiments for our QC stan-
dards composed of MVL. In addition, we have 
safeguarded against potential analyte instability 
by ana lysis of a urine validation sample in each 
batch. However, additional long-term studies 
should be carried out to confirm previous reports 
of analyte stability.
To demonstrate the utility of the validated 
assay MVA was quantified in rat urine col-
lected during the time range 10:00–22:00 or 
22:00–10:00 and in paired morning-evening 
spot collections from healthy children. The 
production of MVA, represented by the plasma 
concentration and urinary excretion, is subject 
to diurnal variation in humans [14,15,32] and the 
hepatic microsomal activity of HMG-CoA 
reductase in rats displays a marked diurnal vari-
ation [14,16]. However, early studies were unable 
to demonstrate a statistically significant diurnal 
fluctuation of plasma MVA in rats [2]. The pres-
ent assay successfully distinguished between two 
12 h rat urine collections, with 22:00–10:00 
collections containing more than threefold the 
amount of MVA than 10:00–22:00 collections. 
These data correspond well to published data 
on the diurnal activity of hepatic HMG-CoA 
reductase [36]. The discrepancy between the 
present data and the lack of significance found 
in the flux of plasma MVA by Kopito et al. is 
likely to do with study design rather than the 
analytical method; in comparison to the present 
study, rats were allowed access to food between 
time points 09:00 and 12:00 and plasma mev-
alonate was measured across nine time points 
with different groups of animals at each time 
point (n = 5–6 per group) [2]. Given the inter-
individual variation displayed between the ani-
mals in the present study, it is more likely that 
significant diurnal fluctuations would have been 
seen if the concentration of plasma MVA over 
time had been compared in samples obtained 
from matched animals.
Our pilot biomarker investigation also quan-
tified MVA in urine obtained by paired morn-
ing and evening spot collection from healthy 
children with a mean age of 9.10 years. In 60% 
of individuals the concentration of MVA was 
greater in the morning spot collection and these 
increases ranged from 27 to 469%. In four 
individuals a significantly lower urinary MVA 
content was observed in the morning compared 
with the evening collection. These data con-
form with published urinary MVA data where 
a study of healthy volunteers observed increases 
of 6 to 122% in MVA excretion in eight of 11 
volunteers in 12 h urine collected between time 
points 19:00 and 07:00 compared with 07:00 
and 19:00; in the remaining three volunteers 
this trend was reversed [37]. Correspondingly, 
plasma MVA was observed to vary fivefold in 
a 40 year old male with a maximum at 07:00 
and a minimum at 22:00 [32]. 
Notably, normalization of the MVA con-
centration to UCr concentration or urine vol-
ume increased the differences between MVA 
excretion observed in the timed collections of 
the rat study. UCr normalization was especially 
important to account for inconsistencies in 
Key Terms
Parallelism: Validation 
parameter used when a 
surrogate matrix is used for 
preparation of calibration 
standards. Multiple dilutions of 
study samples are prepared and 
the analyte(s) are quantified. 
Parallelism between the sample 
and the calibration standard 
matrices is achieved when the 
calculated concentration of the 
diluted samples falls within a 
predefined level of variation 
(typically 20–30%) of the 
expected concentration.
Endogenous biomarkers: 
Naturally occurring measurable 
characteristic that can be used 
as an indicator of a phenotype. 
There are several types 
including efficacy, toxicity, 
mechanistic and susceptibility 
biomarkers. The measurement 
of blood glucose for the 
diagnosis and monitoring of 
type II diabetes or the 
prediction of drug effects such 
as genetic polymorphisms 
associated with differential 
warfarin metabolism are 
examples. The use of 
biomarkers, although well 
established, is increasingly 
important in the path towards 
personalized medicine.
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Executive summary
Background
 Mevalonic acid is produced by the rate-limiting enzyme 3-hydroxy-3-methylglutaryl coenzyme A reductase and is a key metabolic 
intermediate of the mevalonate pathway. 
 The mevalonate pathway and therefore 3-hydroxy-3-methylglutaryl coenzyme A reductase are important mediators of sterol and 
nonsterol biosynthesis, and therefore play an important role in multiple health and disease states.
 The study of mevalonic acid, and any biomarker, would benefit from an accurate, precise, site-transferable and translational method of 
quantification. 
 To this end, a LC–MS/MS quantification assay has been developed and validated according to fit-for-purpose biomarker guidelines. 
Results
 The assay is accurate and precise over a biologically relevant dynamic range allowing quantification of mevalonic acid in human and rat 
urine with a small 50 µl sample volume. 
 The method has been successfully transferred between laboratories with different instruments with minimal optimization required.
Application
 Mevalonic acid demonstrated diurnal urinary excretion patterns in male Sprague-Dawley rats and healthy human children, thus 
illustrating the utility of the method.
urine output between the spot collections from 
the healthy children, as prolonged timed collec-
tions were not practical. However, there is some 
disagreement over the value of creatinine nor-
malization for urine biomarkers in nonsteady 
state diseases such as acute kidney injury [38,39], 
and consideration of the changes in creati-
nine clearance must be made when selecting 
a method of normalization for urinary MVA 
as a biomarker.
Conclusion
The MVA quantification method presented 
here has been validated according to fit-for-pur-
pose guidelines for biomarkers. The method 
displays precision (±15%CV) and accuracy 
(85–115%), and circumvents the bioanalytical 
difficulties of MVA as an analyte – its endog-
enous presence in biofluids and polarity. This 
method is suitable for quantification of endog-
enous MVA in rat and human urine, and can 
be successfully transferred between laboratories 
in support of studies of mevalonate pathway 
flux as a biomarker of disease, pharmacologi-
cal efficacy and response to cellular injury. In 
a prototype biomarker study, urinary excretion 
of MVA by male rats and healthy human chil-
dren was shown to undergo the diurnal varia-
tion predicted by the known diurnal variation 
of hepatic HMG-CoA reductase activity.
Future perspective
With the increasing importance of established 
and novel biomarkers in the realm of disease and 
therapeutics, the field of bioana lysis has had to 
appreciate the difference between quantifying 
drugs and their metabolites and endogenous 
biomarkers. Yet just as in drug quantification, 
consistency between laboratories in the execu-
tion and validation of methods is important to 
the reliability of data, especially if such data 
are to have a clinical impact. For HMG-CoA 
reductase and MVA, their pivotal position in 
cholesterol and isoprenoid biosynthesis makes 
them an interesting target for future disease 
research. As a potential biomarker of multiple 
end-points, the development of a reliable MVA 
quantification method will only enhance trans-
lational research into this limitless area. It is 
hoped that regulatory authorities will formu-
late guidelines for bioanalysts that will clarify 
and compliment the study of endogenous bio-
markers and help progress a biomarker from 
basic research to clinical application.
Supplementary data
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